If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
GSK are in charge of the novel antibodies section of the research
"The consortium has coalesced into five working groups: clinical phase repurposing led by Vessey; preventive vaccines coordinated by Mathai Mammen, global head of R&D for the Janssen Pharmaceutical Cos. unit of Johnson & Johnson (NYSE:JNJ); novel antibodies led by Hal Barron, CSO and president of R&D at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); novel small molecule antivirals headed by Jay Bradner, president of Novartis Institutes for BioMedical Research (NIBR) -- the research arm of Novartis AG (NYSE:NVS; SIX:NOVN); and preclinical repurposing sponsored by Werner Lanthaler, CEO of Evotec."
https://www.thesun.co.uk/news/11458009/trump-coronavirus-vaccine-cure-johnson-and-johnson/
$900 million contract to find a cure for coronavirus awarded to J&J, $700 million of which has been confirmed as going to Janssen, which is the subsidiary of J&J that Hemogenyx have an agreement with for developing new drugs.
https://hemogenyx.com/wp-content/uploads/2018/10/Hemogenyx-Pharma-Plc-Collaboration-with-Johnson-Johnson-Innovation.pdf
Many seem to be unaware of how exactly Hemogenyx are looking to be involved with the UK response to Covid-19.
1) Hemo are developing a test that says whether a person is at HIGH risk or LOW risk from dying if they catch Covid-19.
If successful this could obviously be useful by telling us who is safe to leave lockdown and carry on their daily lives, and who needs to remain locked down. It means only 5% of the population being locked down instead of 100%! Big news would be either that Hemo have successfully made a working test, or that the government have contracted them to use their test.
2) Hemo are offering their humanised mice to test potential treatments for Covid-19, potentially with J&J as they are already partnered.
3) Hemo are testing their own treatments for Cov-19 in house.
Obviously like all companies looking to be involved with CV-19 it's possible (likely even) that their efforts will not be translated into a government contract or successful trial.
From experience in shares I would guess that as soon as the major buy is filled the share price will drop back to 4p-ish over the next month UNLESS news is released by the company.
If news related to their COVID-19 test being used by the government is released then the sky really is the limit.
The test they have been developing predicts which people would be at high risk of serious effects of Covid-19 (including death...) and which people would be lower risk. This would obviously be very useful for government and country because we could let all the people who are low risk stop isolating and get on with normal life. The 5% that are high risk can continue to isolate for the next year or two while the economy, NHS, and daily life gets back to normal for everyone else.